AxioMed Spine financings
This article was originally published in The Gray Sheet
The degenerative spine disease start-up completed a "series D" funding round, collecting $14.5 million from existing and new investors, AxioMed announced July 22. The privately-held company plans to use the funds to complete enrollment of a U.S. pivotal study for its Freedom lumbar disc, which has a CE mark in Europe and has been sold there for the past 12 months. The investment will also help AxioMed expand its sales force for Freedom in Europe, as well as achieve CE mark and support the launch of its cervical disc
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.